We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors.
- Authors
Schepisi, Giuseppe; Conteduca, Vincenza; Casadei, Chiara; Gurioli, Giorgia; Rossi, Lorena; Gallà, Valentina; Cursano, Maria Concetta; Brighi, Nicole; Lolli, Cristian; Menna, Cecilia; Farolfi, Alberto; Burgio, Salvatore Luca; Altavilla, Amelia; Martinelli, Giovanni; De Giorgi, Ugo
- Abstract
Currently, renal cell carcinoma is characterized by encouraging benefits from immunotherapy that have led to significant results in treatment outcome. The approval of nivolumab primarily as second-line monotherapy and, more recently, the approval of new combination therapies as first-line treatment have confirmed the importance of immunotherapy in this type of tumor. In this context, the chimeric antigen receptor (CAR)-T represents a further step forward in the field of immunotherapy. Initially tested on hematological malignancies, this new therapeutic approach is also becoming a topic of great interest for solid tumors. Although the treatment has several advantages over previous T-cell receptor-dependent immunotherapy, it is facing some obstacles in solid tumors such as a hostile tumor microenvironment and on-tumor/off-tumor toxicities. Several strategies are under investigation to overcome these problems, but the approval of CAR-T cell therapy is still some way off. In renal cancer, the significant advantages obtained from immune checkpoint inhibitors represent a good starting point, but the potential nephrological toxicity of CAR-T cell therapy represents an important risk. In this review, we provide the rationale and preliminary results of CAR-T cell therapy in renal cell malignancies.
- Subjects
CHIMERIC antigen receptors; CELLULAR therapy; IMMUNE checkpoint inhibitors; CELL tumors; TREATMENT effectiveness
- Publication
Frontiers in Oncology, 2020, Vol 10, pN.PAG
- ISSN
2234-943X
- Publication type
Article
- DOI
10.3389/fonc.2020.565857